Scientists have created a specialized antiviral chewing gum that demonstrated a near-zero risk reduction for specific head and neck cancers in early trials.
The formulation targets and neutralizes viral agents in saliva before they can cause cellular changes or chronic inflammation.
Researchers express optimism that this low-cost preventative treatment could be integrated into routine public health strategies worldwide.